第一三共株式会社 (Daiichi Sankyo Company, 2015-01-05: Daiichi Sankyo's release states it obtained Japanese manufacturing/marketing approval for Methylene Blue IV 50 mg 'Daiichi Sankyo' with the indication toxic methemoglobinemia on 26 December 2014, and that it licensed exclusive Japanese development and marketing rights from Provepharm SAS of Marseille.
「中毒性メトヘモグロビン血症」を効能・効果として、2014 年 12 月 26 日付で国内製造販売承認を取得しましたのでお知らせいたします。
p.1
第一三共株式会社 (Daiichi Sankyo Company, 2015-01-05: Daiichi Sankyo's release states it obtained Japanese manufacturing/marketing approval for Methylene Blue IV 50 mg 'Daiichi Sankyo' with the indication toxic methemoglobinemia on 26 December 2014, and that it licensed exclusive Japanese development and marketing rights from Provepharm SAS of Marseille. C7 – Japan approval date and licence holder. non-Latin quote, hand-check (Japanese). Translation of the excerpt: 'We announce that we obtained domestic manufacturing and marketing approval dated 26 December 2014, with toxic methemoglobinemia as the indication and effect.' The PDF wraps the line between 承認 and を取得; the line break is removed in the excerpt and the text is otherwise verbatim. Same document, later paragraph (translation): 'The Company obtained exclusive development and marketing rights in Japan from Provepharm SAS (headquarters: Marseille, France) and filed the marketing approval application in March 2014'; it also states the product was taken up by the 医療上の必要性の高い未承認薬・適応外薬検討会議 (committee on unapproved/off-label drugs with high medical need) and that development received a grant from 一般社団法人未承認薬等開発支援センター. The HTML news page (index_5955.html) carries the same date and headline but renders the body only in the linked PDF, which was opened with pdftotext. The PDF's text layer sets the Japanese release almost one glyph per line, so the excerpt matches only when whitespace is ignored; checked that way, character for character. non-Latin quote, hand-check. Study type: news.
